Angiotensin Neprilysin Inhibition for Patients With Heart Failure What If Sacubitril/Valsartan Were a Treatment for Cancer?

被引：18
|
作者：
Packer, Milton [1 ]
机构：
[1] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, 621 N Hall St, Dallas, TX 75226 USA
来源：
JAMA CARDIOLOGY | 2016年 / 1卷 / 09期
关键词：
ENALAPRIL;
D O I：
10.1001/jamacardio.2016.3053
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [41] Sacubitril/Valsartan (Entresto) for Heart Failure
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (07): : 722 - 723
  • [42] The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update
    Nielsen, Peter Munch
    Grimm, Daniela
    Wehland, Markus
    Simonsen, Ulf
    Krueger, Marcus
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 9 - 18
  • [43] Sacubitril/valsartan (LCZ696) for the treatment of heart failure
    Gori, Mauro
    Senni, Michele
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2016, 14 (02) : 145 - 153
  • [44] COST-UTILITY ANALYSIS OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR SACUBITRIL/VALSARTAN COMPARED WITH ACE INHIBITORS FOR THE TREATMENT OF CHRONIC HEART FAILURE IN THE UNITED STATES
    Harrington, R. L.
    Zueger, P. M.
    Kumar, V. M.
    Rigoni, G.
    Atwood, A. M.
    DiDomenico, R. J.
    Touchette, D. R.
    VALUE IN HEALTH, 2016, 19 (03) : A49 - A49
  • [45] Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Del Buono, Marco Giuseppe
    Bonaventura, Aldo
    Vecchie, Alessandra
    Wohlford, George F.
    Dixon, Dave L.
    Van Tassel, Benjamin W.
    Abbate, Antonio
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (02) : 105 - 107
  • [46] The safety of sacubitril-valsartan for the treatment of chronic heart failure
    Tyler, Jeffrey M.
    Teerlink, John R.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 257 - 263
  • [47] Sacubitril-Valsartan for the Treatment of Heart Failure Effectiveness and Value
    Ollendorf, Daniel A.
    Sandhu, Alexander T.
    Pearson, Steven D.
    JAMA INTERNAL MEDICINE, 2016, 176 (02) : 249 - 250
  • [48] Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan
    Chang, Po-Cheng
    Wang, Chun-Li
    Hsiao, Fu-Chih
    Wen, Ming-Shien
    Huang, Chien-Ying
    Chou, Chung-Chuan
    Chu, Pao-Hsien
    ESC HEART FAILURE, 2020, 7 (05): : 3003 - 3012
  • [49] Renin-angiotensin-aldosterone fingerprint in treatment of heart failure with preserved ejection fraction with sacubitril/valsartan
    Dachs, T.
    Nagele, F.
    Rettl, R.
    Poglitsch, M.
    Dalos, D.
    Duca, F.
    Binder-Rodriguez, C.
    Camuz-Ligios, L.
    Dusik, F.
    Seirer, B.
    Hengstenberg, C.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S207 - S207
  • [50] In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
    Jovanovic, Jelena Dorovic
    Antonijevic, Marko
    Vojinovic, Radisa
    Filipovic, Nenad D.
    Markovic, Zoran
    RSC ADVANCES, 2022, 12 (46) : 29719 - 29726
12345